Histogen, Inc. is a clinical-stage regenerative medicine company focused on developing and commercializing proprietary, biologically derived products for aesthetic and therapeutic applications. Leveraging its proprietary NightTime Biology™ platform, Histogen cultivates human cells under low-oxygen, low-temperature conditions that mimic the embryonic environment, stimulating the production of growth factors, extracellular matrix proteins and exosomes. The company’s pipeline targets a range of dermatological and medical conditions, including hair loss, acne scarring and wound healing.
The company’s leading programs include HST001, an injectable formulation intended to promote hair follicle regeneration in patients suffering from androgenetic alopecia, and HST504, which is being evaluated for its potential to improve the appearance of facial acne scars. Both candidates harness the bioactive factors naturally secreted by cells grown under NightTime Biology conditions, avoiding the need for live cell transplantation. Histogen has conducted multiple Phase I and II studies to assess safety, tolerability and preliminary efficacy, and continues to advance these assets toward pivotal trials and commercial readiness.
Founded in 2008 and headquartered in San Diego, California, Histogen maintains research and manufacturing facilities in both the United States and Europe. The company collaborates with leading contract research organizations, academic institutions and manufacturing partners to support its translational efforts and ensure scalable production of its biologic formulations. These partnerships underpin Histogen’s goal of delivering off-the-shelf regenerative therapies that address unmet needs in dermatology and beyond.
Under the leadership of Chief Executive Officer Charles Butler, Histogen is managed by a team of executives with extensive experience in biotechnology, clinical development and regulatory affairs. The board and management team are focused on advancing late-stage programs, securing strategic partnerships and preparing for product commercialization. With its novel approach to harnessing the body’s natural repair mechanisms, Histogen aims to establish itself as a leader in the regenerative medicine and aesthetic dermatology markets.
AI Generated. May Contain Errors.
Free HSTO Stock Alerts